GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring human peptide with over four decades of published research behind it. At TelosRX, protocols involving GHK-Cu are subject to provider evaluation — this article summarizes what the published evidence actually shows.
GHK-Cu is found naturally in human plasma, saliva, and urine. Plasma concentrations average around 200 ng/mL at age 20 but decline to approximately 80 ng/mL by age 60 — a pattern that has sparked interest in its potential role in aging-related tissue changes. The compound is not FDA-approved for therapeutic use as a compounded preparation.
What follows is a structured walk through the published literature: what studies examined, what they found, and the limitations of the current evidence base.
What Is GHK-Cu and How Does It Signal Tissue Repair?
GHK (glycyl-L-histidyl-L-lysine) is a tripeptide naturally released from proteins during tissue injury. It binds copper(II) ions with high affinity, forming the GHK-Cu complex. In the body, elevated GHK concentrations at wound sites appear to act as a biochemical signal for repair initiation — recruiting fibroblasts, stimulating extracellular matrix production, and modulating the inflammatory response.
The copper component is essential. Copper is a required cofactor for lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin fibers to create mechanical strength. Without adequate copper, newly synthesized collagen remains structurally weak.
For context on how peptides generally interact with tissue repair, see our article on peptides studied for tendon repair.
Finding 1: Fibroblast Stimulation and Collagen Synthesis
The most replicated finding in GHK-Cu research is its stimulation of fibroblast activity. A foundational 1985 study by Maquart et al. published in FEBS Letters found that GHK-Cu stimulated collagen synthesis in human fibroblast cultures at concentrations as low as 10⁻¹² M, with the effect maximizing around 10⁻⁹ M (PubMed PMID 3169264).
Subsequent work showed GHK-Cu's effects extend beyond simple collagen quantity. A later study found that GHK-Cu simultaneously increases matrix metalloproteinase-2 (MMP-2) expression in fibroblast cultures — an enzyme involved in remodeling and clearing damaged collagen, not only producing new fibers (PubMed PMID 11045606). This dual stimulation of synthesis and remodeling suggests GHK-Cu may support the full extracellular matrix repair cycle, not just initial deposition.
In human skin explant models, palmitoylated GHK derivatives showed collagen synthesis increases of up to 75% measured by radiolabeled proline incorporation — though this involved a modified compound, not native GHK-Cu.
Finding 2: In Vivo Wound Closure Evidence
Animal and human studies have examined whether GHK-Cu's in vitro fibroblast effects translate to wound healing in living tissue. A 1993 study published in PNAS demonstrated that topically applied GHK-Cu increased connective tissue accumulation in rat experimental wounds compared to vehicle controls (PMC288419). The treated wounds showed greater glycosaminoglycan and collagen accumulation.
More recent preclinical work in scald injury models found that liposomal GHK-Cu formulations reduced wound closure time to approximately 14 days post-injury, with stronger CD31 (vascular marker) and Ki67 (cellular proliferation marker) staining relative to controls — suggesting enhanced angiogenesis and tissue regeneration. These findings are preclinical; direct extrapolation to human wound healing requires caution.
Clinical data in humans is more limited. Published case series and small trials have examined GHK-Cu preparations in diabetic wound care and post-surgical healing, with generally favorable results, but controlled trial data remains sparse by pharmaceutical standards.
Finding 3: Anti-Inflammatory Mechanisms
GHK-Cu research has identified several anti-inflammatory mechanisms at the molecular level. Studies show GHK-Cu reduces NF-κB pathway activation — a central switch for pro-inflammatory cytokine production including TNF-α, IL-1β, and IL-6.
Additionally, research suggests GHK-Cu promotes macrophage phenotype transition: shifting cells from the M1 (pro-inflammatory, early wound) phenotype toward the M2 (anti-inflammatory, tissue-remodeling) phenotype at the appropriate repair stage. This is relevant because dysregulated M1 macrophage persistence is associated with chronic wounds and scarring.
A 2008 review in the Journal of Peptide Science summarized that GHK modulates both synthesis and degradation of collagen and glycosaminoglycans, and regulates the activity of metalloproteinases and their inhibitors — essentially orchestrating multiple layers of the tissue remodeling response (PubMed PMID 18644225).
| Research Area | Key Finding | Evidence Level |
|---|---|---|
| Collagen synthesis | Stimulates fibroblasts at picomolar concentrations; increases collagen I/III | In vitro (replicated) |
| MMP-2 expression | Upregulates matrix remodeling enzyme alongside synthesis | In vitro |
| Wound closure | Increased connective tissue accumulation in rat wound models | Animal (in vivo) |
| Anti-inflammation | Reduces NF-κB activation; shifts macrophages toward M2 phenotype | In vitro / preclinical |
| Gene regulation | May modulate activity of over 4,000 human genes per bioinformatics analysis | Database analysis |
Finding 4: Gene Regulation — The Large-Scale Database Analysis
A 2018 paper by Pickart and Margolina analyzed GHK-Cu against the LINCS (Library of Integrated Network-Based Cellular Signatures) database — a large-scale genomic resource — and found that GHK-Cu gene expression signatures overlapped with pathways involved in tissue remodeling, inflammatory regulation, and anti-cancer activity. The analysis suggested potential activity across over 4,000 human genes (PMC6073405).
This is an important result with important caveats. Database-level bioinformatics analysis identifies correlations between gene expression patterns; it does not establish causation, dose-response, or clinical outcomes in humans. These findings generated hypotheses for further study, not proven mechanisms.
For context on how GHK-Cu compares as a broad tissue-support peptide to other compounds, see our GHK-Cu telehealth guide.
Research Limitations and Clinical Context
The GHK-Cu literature has real strengths: decades of consistent in vitro results, multiple independent research groups, and clear mechanistic hypotheses. It also has real gaps.
- Human RCT data is limited: most wound healing evidence comes from animal models or small, uncontrolled human case series
- Delivery challenge: GHK-Cu's bioavailability via injectable vs. topical vs. oral routes varies substantially; most published studies use topical or injected forms
- Regulatory status: GHK-Cu is not FDA-approved as a therapeutic compound; as a compounded preparation, it is not FDA-approved and is prepared under federal compounding regulations
- Dosing standards: no established clinical dosing protocol exists; protocols vary widely across the research literature
Any GHK-Cu protocol at TelosRX is subject to evaluation and approval by a licensed provider. The evidence reviewed here is informational and does not constitute a treatment claim. The research summarized involves preclinical and limited clinical data; it does not establish that any specific outcome will occur.
Interested in how other recovery-focused peptides compare? See our research overview on BPC-157 peptide research.
Frequently Asked Questions
What does GHK-Cu stand for?
GHK-Cu stands for glycyl-L-histidyl-L-lysine copper. GHK is a naturally occurring tripeptide found in human plasma and tissues; the "Cu" refers to copper(II) ions it binds. The complex forms at wound sites and in areas of tissue turnover, where it appears to signal repair processes.
Is GHK-Cu FDA-approved?
No. GHK-Cu is not FDA-approved as a therapeutic drug. As a compounded preparation, it is not FDA-approved and is prepared under federal compounding pharmacy regulations. Any protocol involving compounded GHK-Cu requires provider evaluation and approval before use.
What does the research show about GHK-Cu for wound healing?
Published studies show GHK-Cu stimulates fibroblast activity and collagen synthesis in vitro, and increases connective tissue accumulation in animal wound models. Clinical human data is limited to small case series. The evidence is promising but not sufficient to make definitive outcome claims.
How does GHK-Cu affect collagen production?
In fibroblast culture studies, GHK-Cu stimulates collagen synthesis beginning at picomolar concentrations, with effects peaking around 10⁻⁹ M. It also upregulates matrix metalloproteinase-2 (MMP-2), which is involved in remodeling existing collagen — suggesting dual activity on synthesis and tissue organization.
What are the anti-inflammatory effects of GHK-Cu?
Research shows GHK-Cu reduces NF-κB pathway activation (a key driver of inflammation) and appears to promote the transition of macrophages from pro-inflammatory M1 to tissue-remodeling M2 phenotype. These effects are documented in in vitro and preclinical models; human clinical data is limited.
How does GHK-Cu decline with age?
Plasma GHK concentrations average approximately 200 ng/mL at age 20 and decline to around 80 ng/mL by age 60. This age-related decline has generated interest in whether supplemental GHK-Cu might offset some aging-related changes in tissue repair capacity, though causation has not been established.
Can I access GHK-Cu through TelosRX?
TelosRX is an online-first, asynchronous telehealth pharmacy. Protocols involving compounded GHK-Cu are subject to evaluation by a licensed provider. Compounded GHK-Cu is not FDA-approved. Approval is not guaranteed. Submit an intake to begin the provider review process.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.